Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | PREP | P48147 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798467 | 0.85 | CHRM2 (0.62) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL699339 | 0.79 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL3424501 | 0.74 | CHRNB2 (0.50) | CHRM2CHRM1CHRM3HSD11B1CHRNB2 | |
| SCHEMBL699340 | 0.73 | CHRM2 (0.38) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL31285244 | 0.72 | CHRM2 (0.61) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL3426401 | 0.71 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL20773410 | 0.69 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPEPHX2 | |
| SCHEMBL20773468 | 0.69 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL20773346 | 0.68 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL15149089 | 0.68 | CHRM2 (0.51) | CHRM2CHRM1CHRM3HSD11B1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-8329909-B2 | Method for producing 2-azaadamantane compound from bicyclocarbamate compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120053348-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2423212-A1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053348-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | CNKSR1, HDAC11, HDAC1 | CHRM2 187/4885CHRM1 319/4885CHRM3 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.